Outcome of liver cancer patients with SARS-CoV-2 infection : An International, Multicentre, Cohort Study
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd..
BACKGROUND & AIMS: Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.
METHODS: Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.
RESULTS: Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection.
CONCLUSIONS: This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Liver international : official journal of the International Association for the Study of the Liver - 42(2022), 8 vom: 01. Aug., Seite 1891-1901 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 25.07.2022 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/liv.15320 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34131398X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34131398X | ||
| 003 | DE-627 | ||
| 005 | 20240320232742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/liv.15320 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM34131398X | ||
| 035 | |a (NLM)35608939 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muñoz-Martínez, Sergio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcome of liver cancer patients with SARS-CoV-2 infection |b An International, Multicentre, Cohort Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.07.2022 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Liver International published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND & AIMS: Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population | ||
| 520 | |a METHODS: Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered | ||
| 520 | |a RESULTS: Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection | ||
| 520 | |a CONCLUSIONS: This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a liver cancer | |
| 650 | 4 | |a mortality | |
| 700 | 1 | |a Sapena, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Forner, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Bruix, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Sanduzzi-Zamparelli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ríos, José |e verfasserin |4 aut | |
| 700 | 1 | |a Bouattour, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a El-Kassas, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Leal, Cassia R G |e verfasserin |4 aut | |
| 700 | 1 | |a Mocan, Tudor |e verfasserin |4 aut | |
| 700 | 1 | |a Nault, Jean-Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Alves, Rogerio C P |e verfasserin |4 aut | |
| 700 | 1 | |a Reeves, Helen L |e verfasserin |4 aut | |
| 700 | 1 | |a da Fonseca, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a García-Juárez, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Varela, María |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Saleh A |e verfasserin |4 aut | |
| 700 | 1 | |a Alvares-da-Silva, Mario R |e verfasserin |4 aut | |
| 700 | 1 | |a Bandi, Juan C |e verfasserin |4 aut | |
| 700 | 1 | |a Rimassa, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a González Santiago, Jesús M |e verfasserin |4 aut | |
| 700 | 1 | |a Tacke, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Sala, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Anders, María |e verfasserin |4 aut | |
| 700 | 1 | |a Lachenmayer, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Piñero, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a França, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Guarino, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Elvevi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Cabibbo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Peck-Radosavljevic, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas, Ángela |e verfasserin |4 aut | |
| 700 | 1 | |a Vergara, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Braconi, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Perelló, Christie |e verfasserin |4 aut | |
| 700 | 1 | |a Mello, Vivianne |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Lope, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Acevedo, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Villani, Rosanna |e verfasserin |4 aut | |
| 700 | 1 | |a Hollande, Clemence |e verfasserin |4 aut | |
| 700 | 1 | |a Vilgrain, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Tawheed, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Ferguson Theodoro, Carmem |e verfasserin |4 aut | |
| 700 | 1 | |a Sparchez, Zeno |e verfasserin |4 aut | |
| 700 | 1 | |a Blaise, Lorraine |e verfasserin |4 aut | |
| 700 | 1 | |a Viera-Alves, Daniele E |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Robyn |e verfasserin |4 aut | |
| 700 | 1 | |a Carrilho, Flair J |e verfasserin |4 aut | |
| 700 | 1 | |a Moctezuma-Velázquez, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a D'Alessio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Iavarone, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Reig, Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver international : official journal of the International Association for the Study of the Liver |d 2003 |g 42(2022), 8 vom: 01. Aug., Seite 1891-1901 |w (DE-627)NLM124147356 |x 1478-3231 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:8 |g day:01 |g month:08 |g pages:1891-1901 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/liv.15320 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 8 |b 01 |c 08 |h 1891-1901 | ||